Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

doi:10.1016/j.lungcan.2007.05.017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2007

Costa Daniel B, Kobayashi Susumu, Tenen Daniel G, Huberman Mark S

Abstract excerpt

PURPOSE: Epidermal growth factor receptor (EGFR) mutations have been found in the majority of gefitinib-responsive non-small cell lung cancer (NSCLC) patients from retrospective studies. We sought to compile the available phase II and prospective trials of this EGFR tyrosine kinase inhibitor (TKI...

Topics

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Chemotherapy, Adjuvant
Clinical Trials, Phase II as Topic
Disease-Free Survival
ErbB Receptors
Gefitinib
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Mutation
Neoplasm Staging
Prospective Studies
Protein Kinase Inhibitors
Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 17610986
DOI: 10.1016/j.lungcan.2007.05.017
PMCID: PMC2551312

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-17610986-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics